243 related articles for article (PubMed ID: 28560458)
21. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
22. The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.
Meriggi F; Vermi W; Bertocchi P; Zaniboni A
Rev Recent Clin Trials; 2014; 9(1):8-12. PubMed ID: 24758538
[TBL] [Abstract][Full Text] [Related]
23. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
24. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.
De Robertis M; Loiacono L; Fusilli C; Poeta ML; Mazza T; Sanchez M; Marchionni L; Signori E; Lamorte G; Vescovi AL; Garcia-Foncillas J; Fazio VM
Clin Cancer Res; 2017 Jan; 23(1):159-170. PubMed ID: 27401248
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.
Janku F; Wheler JJ; Hong DS; Kurzrock R
Target Oncol; 2013 Sep; 8(3):183-188. PubMed ID: 23400451
[TBL] [Abstract][Full Text] [Related]
26. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
27. Alteration of the EphA2/Ephrin-A signaling axis in psoriatic epidermis.
Gordon K; Kochkodan JJ; Blatt H; Lin SY; Kaplan N; Johnston A; Swindell WR; Hoover P; Schlosser BJ; Elder JT; Gudjonsson JE; Getsios S
J Invest Dermatol; 2013 Mar; 133(3):712-722. PubMed ID: 23190894
[TBL] [Abstract][Full Text] [Related]
28. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
29. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
[TBL] [Abstract][Full Text] [Related]
30. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.
Lindner AU; Carberry S; Monsefi N; Barat A; Salvucci M; O'Byrne R; Zanella ER; Cremona M; Hennessy BT; Bertotti A; Trusolino L; Prehn JHM
Int J Cancer; 2020 Nov; 147(10):2891-2901. PubMed ID: 32700762
[TBL] [Abstract][Full Text] [Related]
31. Truncated EphA2 likely potentiates cell adhesion via integrins as well as infiltration and/or lodgment of a monocyte/macrophage cell line in the red pulp and marginal zone of the mouse spleen, where ephrin-A1 is prominently expressed in the vasculature.
Konda N; Saeki N; Nishino S; Ogawa K
Histochem Cell Biol; 2017 Mar; 147(3):317-339. PubMed ID: 27665280
[TBL] [Abstract][Full Text] [Related]
32. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
33. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
34. Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.
Efazat G; Novak M; Kaminskyy VO; De Petris L; Kanter L; Juntti T; Bergman P; Zhivotovsky B; Lewensohn R; Hååg P; Viktorsson K
Oncotarget; 2016 Sep; 7(37):60332-60347. PubMed ID: 27533087
[TBL] [Abstract][Full Text] [Related]
35. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
36. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis.
Dohn M; Jiang J; Chen X
Oncogene; 2001 Oct; 20(45):6503-15. PubMed ID: 11641774
[TBL] [Abstract][Full Text] [Related]
37. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
Bahrami A; Hassanian SM; ShahidSales S; Farjami Z; Hasanzadeh M; Anvari K; Aledavood A; Maftouh M; Ferns GA; Khazaei M; Avan A
J Cell Physiol; 2018 Mar; 233(3):2058-2066. PubMed ID: 28262927
[TBL] [Abstract][Full Text] [Related]
38. EphA2 Transmembrane Domain Is Uniquely Required for Keratinocyte Migration by Regulating Ephrin-A1 Levels.
Ventrella R; Kaplan N; Hoover P; Perez White BE; Lavker RM; Getsios S
J Invest Dermatol; 2018 Oct; 138(10):2133-2143. PubMed ID: 29705292
[TBL] [Abstract][Full Text] [Related]
39. Restriction of receptor movement alters cellular response: physical force sensing by EphA2.
Salaita K; Nair PM; Petit RS; Neve RM; Das D; Gray JW; Groves JT
Science; 2010 Mar; 327(5971):1380-5. PubMed ID: 20223987
[TBL] [Abstract][Full Text] [Related]
40. Use of a High-Throughput Genotyping Platform (OncoMap) for
Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW
Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
